Skip to main content
OpenTrials
Completed

NCT Number: NCT01692847

Examination of the Impact of Better Surveillance and Communication of Patient Deterioration on Patient Related Outcomes

A hospitals manual method of patient monitoring will be implemented in an automated system and supported by an early patient deterioration detection for timely escalation. The purpose of this study is to assess if clinical outcomes of patients in Acute Care are significantly improved by such a system.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Severe Sepsis Cardiac Arrest Cardiovascular Diseases Heart Arrest Heart Diseases Infections Inflammation Pathologic Processes Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Failure Respiratory Insufficiency Respiratory Tract Diseases Sepsis Systemic Inflammatory Response Syndrome

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ysbyty Gwynedd Hospital

Bangor, Penrhosgarnedd, LL572PW, United Kingdom

About this study

The purpose of this study is to assess if the Philips IntelliVue Guardian Solution (IGS) with all its components can significantly improve clinical outcomes for deteriorating patients on a general medical ward prior and after referral to the hospitals' Acute Care Team (ACT). Further, to provide evidence that the Philips IGS assists to increase the efficiency of a hospital's Early Warning Scoring process (afferent and efferent arm of the escalation system).

The introduction of such an intelligent automated system offers a unique opportunity to address the breakdown in the chain of prevention by strengthening the reliability of calls-for-help to responders through a technical solution with the potential for a more timely escalation where appropriate.

In this study the hospital's Standard of Care protocol for the monitoring of vital signs (including timing, vital signs collected and escalation instructions) will be implemented in a commercially available intelligent automatic monitoring and notification system. No investigational procedures or devices are associated with this protocol.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • all patients admitted to the study units during the period of data collection

Exclusion criteria

  • less than 24h on ward

Treatment and study plan

Primary outcomes

  1. Improvement of outcome for patients after implementing the IGS

    Time frame: 15 months

    Does the IGS significantly increase positive outcomes for deteriorating patients after referral to the RRT/ACT as measured by the MAELOR score

Secondary outcomes

  1. Early detection of patient deterioration

    Time frame: 15 months

    Does the IGS detect patient deterioration earlier and therefore prevent or shorten periods of severe illness.

  2. Daily workload for the ward's personnel

    Time frame: 15 months

    Does the IGS reduce the daily workload related to patient surveillance for the general ward personnel.

  3. Level of satisfaction

    Time frame: 15 months

    Do Nurses and Doctors express a higher level of satisfaction with the IGS in place than with their current paper-based surveillance.

Sponsors and collaborators

Lead sponsor

Philips Healthcare

Industry

Registry information

Official study title

Examination of the Impact of Better Surveillance and Communication of Patient Deterioration on Patient Related Outcomes (VitalCare - Guardian Version 2)

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Sep 25, 2012
Registry last updated
Apr 4, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.